Compare Incyte Corporation (INCY) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Opendoor Technologies Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Opendoor Technologies Inc trades at $4.48 (market cap $4.29B). The key difference: Incyte Corporation is far larger — about 5.4× Opendoor Technologies Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.
| INCY | OPEN | |
|---|---|---|
Market Cap | $23.11B | $4.29B |
Sector | Health | Real Estate |
52-Week High | $118.52 | $10.52 |
52-Week Low | $67.38 | $1.84 |
Enterprise Value | $19.13B | $4.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Opendoor Technologies (OPEN) trades at $4.48, down 0.44% on the day, with a bearish technical outlook and mixed fundamental signals. The stock shows a low price-to-sales ratio of 0.93 but suffers from significant losses, with a net income margin of -35.25% and negative ROE of -173.61%. Recent earnings have been volatile, missing estimates in Q1 2026. Cash flow improved in 2025 with net cash flow of $538 million, though revenue declined to $4.37 billion. News highlights include the upcoming Q2 2026 earnings report and strategic shifts like closing India operations to focus on AI.
The outlook remains challenging due to persistent losses and a tough housing market, but cost-cutting and operational adjustments under new CEO Kaz Nejatian offer potential for margin improvement. Risks include high debt, competitive pressure from Zillow, and interest rate sensitivity. Analyst sentiment is cautious with 65.39% hold ratings, reflecting uncertainty about sustainable profitability. Investors should weigh the low valuation against execution risks in a volatile sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
